Skip to main content

Plus Therapeutics to Present at the YAFO Access China Partnering Conference on July 30, 2020

Written by Customer Service on . Posted in Public Companies.

AUSTIN, Texas, July 23, 2020 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will be presenting at the YAFO ACCESS CHINA – 2020 Summer Online Partnering Day on Thursday, July 30 at 10:00 pm EST.  Dr. Marc Hedrick, President and CEO of Plus Therapeutics, will be hosting the presentation and answering questions from investors.
To access the live presentation, please use the following information:If you would like to register for the event, you may purchase a free Live Day Attendee Ticket or Video on Demand Attendee Ticket here:
https://www.eventbrite.com/e/access-china-2020-summer-online-partnering-day-tickets-106868540682If investors are unable to make the live presentation, a replay-day will be arranged one week later and a link will be posted to the Company’s website.About YAFO Life ScienceYAFO Life Science is the healthcare division of YAFO Capital, a Shanghai-based investment bank boutique and investment firm focused on Life Sciences. YAFO organizes every year ACCESS CHINA Forum event series providing online corporate access through its proprietary deal-making platform, which covers 2,000+ BD directors and executives from Chinese biopharma, healthcare, and investment firms. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing, or commercial collaborations. Together with its co-organizers and partners, YAFO Life Science helps Western biopharma companies efficiently present their assets online in front of 500+ healthcare companies and VCs in China.About Plus Therapeutics, Inc.Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionucleotides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at www.plustherapeutics.com and at www.respect-trials.comContact:Plus Therapeutics, Inc. 
Andrew Sims
VP – Chief Financial Officer, Investor Relations
Phone: +1.619.333.4150
Email: ir@plustherapeutics.com
Corporate Website: plustherapeutics.com
Clinical Website: respect-trials.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.